Executive Vice President and Chief Financial Officer of NewLink Genetics Corporation, a public biotechnology company, from October 2014 to July 2018, and Chief Administrative Officer of NewLink from July 2018 through his retirement in November 2018 Various offices of Integra LifeSciences Holdings Corp., a medical devices company, from 1998 to 2014, including Chief Financial Officer from 2007 to 2014, and earlier as General Counsel and Chief Administrative Officer Recent Public Company Board Service Aprea Therapeutics Inc. (Nasdaq: APRE), a biotechnology company focused on novel cancer therapeutics, from August 2019 to present Orthofix Medical, Inc. (Nasdaq: OFIX), a leading global spine and orthopedics company, from January 2023 to present R1 RCM, Inc. (Nasdaq: RCM), a provider of revenue cycle management services to healthcare providers, from February 2016 through completion of privatization transaction in November 2024 (lead independent director from February 2022 to November 2024) SeaSpine Holdings Corporation (Nasdaq: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, from July 2015 through completion of the merger and acquisition by Orthofix Medical Inc. in January 2023 Education J.D. from University of Michigan Law School A.B. in Politics from Princeton University Relevant Skills Medical Devices/Pharmaceutical Experience and M&A/Business Development Expertise developed during his more than 25 years of senior management experience in the medical technology and biotechnology industries, including at Integra, where he led or executed more than 40 acquisitions and alliances and raised more than $1 billion in debt and equity financing Financial Oversight/Accounting Expertise acquired while serving as Executive Vice President and Chief Financial Officer of NewLink Genetics and as Chief Financial Officer of Integra, positions in which he was responsible for overseeing all the financial aspects of the company s operations Human Capital Management Expertise and Regulatory Expertise gained in his role as General Counsel at Integra and his multiple roles as CFO, especially at Integra, where while serving in that role, he had the additional responsibility, at various times, for the company s regulatory affairs and human resources functions Public Company Governance/Corporate Responsibility Expertise obtained through his significant experience serving on boards of directors, including boards of publicly held life science companies Mr. Henneman also brings International/Global Business Experience to the Board